Giulio Francolini/urotoday.com
May 4, 2025, 12:33
Giulio Francolini: QoL data from DART trial
Giulio Francolini, Radiation Oncologist at Careggi University Hospital, shared a post on X:
“QoL data from DART trial (SBRT+/- darolutamide in oligorec. pCa).
Global health and most QoL subdomains remained stable in both arms over the 24-week period.
More fatigue and hormonal treatment-related symptoms were observed in the SBRT and DARO arm, ESTRO.”
The post presents updated findings from the DART trial, indicating stable quality of life across both study arms over 24 weeks.
However, patients receiving both SBRT and darolutamide experienced increased fatigue and hormonal symptoms.
Stay tuned to OncoDaily for continued coverage and updates from ESTRO25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 20, 2025, 17:22
May 20, 2025, 16:37
May 20, 2025, 16:27
May 20, 2025, 15:05